CVS Health Corporation CVS
Set alert
88.51 USD -1.74 -1.93%
At close
88.52 +0.01 +0.01%
Pre-market · Nov 3, 5:23 AM ET
87.88 Day range 90.62
69.51 52-week range 110.68
- YTD
- +11.53%
- 1 year
- +12.84%
- Open
- 90.23
- Prev close
- 90.25
- Mkt cap
- 113.20B
- Vol
- 9.70M
- Avg vol
- 7.96M
- EPS
- 3.80
- P/E
- 23.29
- Div yield
- 2.94%
More statistics
- Low
- 87.88
- High
- 90.62
- Forward P/E
- 10.37
- Beta
- 0.58
- Short ratio
- 1.63
- Inst. own
- 90.99%
- Dividend
- 2.66
- Ex-div date
- Oct 21, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 91.23
- 200-d avg
- 88.79
- 1y target
- 115.48
5Y chart
Events in this range
- Jan 20, 2022Dividend: 0.55
- Apr 21, 2022Dividend: 0.55
- Jul 21, 2022Dividend: 0.55
- Oct 20, 2022Dividend: 0.55
- Jan 19, 2023Dividend: 0.605
- Apr 20, 2023Dividend: 0.605
- Jul 20, 2023Dividend: 0.605
- Oct 19, 2023Dividend: 0.605
- Oct 20, 2023Dividend: 0.605
- Jan 19, 2024Dividend: 0.665
- Apr 19, 2024Dividend: 0.665
- Jul 22, 2024Dividend: 0.665
- Oct 21, 2024Dividend: 0.665
- Jan 23, 2025Dividend: 0.665
- Apr 22, 2025Dividend: 0.665
- Jul 22, 2025Dividend: 0.665
- Jul 31, 2025Earnings: 1.81; estimate 1.46; surprise 23.97%
- Oct 23, 2025Dividend: 0.665
- Oct 29, 2025Earnings: 1.6; estimate 1.37; surprise 16.79%
- Jan 22, 2026Dividend: 0.665
- Feb 10, 2026Earnings: 1.09; estimate 1; surprise 9%
- Apr 23, 2026Dividend: 0.665
- May 6, 2026Earnings: 2.57; estimate 2.18; surprise 17.89%
- Jul 23, 2026Dividend: 0.665
- Aug 5, 2026Earnings: 2.58; estimate 1.85; surprise 39.46%
- Aug 6, 2026Rating: Evercore ISI Group · Outperform → Outperform
- Aug 6, 2026Rating: UBS · Buy → Buy
- Aug 12, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 19, 2026Rating: Argus Research · Buy → Buy
- Sep 3, 2026Rating: UBS · Buy → Buy
- Oct 12, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 22, 2026Dividend: 0.665
- Nov 4, 2026Earnings: —; estimate 1.65; surprise —%
Signals (114)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
Newest 20 of 114.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 115.48 +30.5% upside
Now 88.51
- Target (low)
- 103.00
- Target (mean)
- 115.48
- Target (high)
- 145.00
Ratings (0m) 27 25 buy · 2 hold · 0 sell
- Strong buy7
- Buy18
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 27
- 1 month ago 27
- 2 months ago 27
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.65 | 1.52 – 1.87 | 1.60 | +3.2% | 104.69B | +1.8% | 23 |
| Next quarter | 1.24 | 1.08 – 1.36 | 1.09 | +14.1% | 106.86B | +1.1% | 23 |
| Current year | 8.04 | 7.94 – 8.15 | 6.75 | +19.1% | 417.87B | +3.9% | 25 |
| Next year | 8.54 | 8.43 – 9.05 | 8.04 | +6.1% | 430.08B | +2.9% | 26 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 3, 2026 | UBS | Maintained | Buy | Buy |
| Aug 19, 2026 | Argus Research | Maintained | Buy | Buy |
| Aug 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 6, 2026 | UBS | Maintained | Buy | Buy |
| Aug 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 24, 2026 | UBS | Maintained | Buy | Buy |
| Jul 14, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jul 13, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 9, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 7, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jun 23, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jun 8, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 4, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jun 1, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 26, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 20, 2026 | Mizuho | Maintained | Outperform | Outperform |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 13, 2026 | Bernstein | Maintained | Outperform | Outperform |
| May 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 11, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 7, 2026 | UBS | Maintained | Buy | Buy |
| May 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 7, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 15, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 31, 2026 | Piper Sandler | Maintained | Overweight | Overweight |